Organic & Biomolecular Chemistry



PAPER

Cite this: Org. Biomol. Chem., 2014, **12**, 1405

Palladium catalyzed acetoxylation of benzylic C–H bonds using a bidentate picolinamide directing group†

Tao Cheng,^a Weiyu Yin,^a Yi Zhang,^a Yingnan Zhang^b and Yong Huang^{*a}

Received 6th November 2013, Accepted 19th December 2013 DOI: 10.1039/c3ob42196a A general palladium catalyzed acetoxylation of benzylic C–H bonds has been developed. Picolinamides serve as an excellent directing group for the C–H activation of benzylic methyls. A wide range of 2-amino benzyl alcohol analogues were synthesized in good yields. The products demonstrated broad synthetic utilities toward various benzo-fused heterocycles. Mechanistic studies revealed the key rate-limiting C–H insertion step, which could be affected by the substitution pattern of the parent arene.

Introduction

www.rsc.org/obc

Transition metal catalyzed selective C-H bond activation reactions have mushroomed into one of the most actively studied areas for creating carbon-carbon and carbon-heteroatom bonds in the past decade.¹ While the major effort was devoted to developing novel directing groups and bond formation reactions surrounding sp² C-H bonds, functionalization of sp³ C-H bonds has also enjoyed impressive progress.² In particular, various directing groups have been invented to selectively convert a sp³ C-H to a C-O functionality for a wide spectrum of substrates.3 However, a general approach for benzylic oxidation remains scarce,⁴ despite the tremendous synthetic capability of substituted benzyl alcohols, which are indispensable synthons toward benzo-heterocycles. Herein, we report a general protocol for benzylic acetoxylation via palladium catalyzed sp³ C-H activation for the synthesis of various 2-amino benzyl acetates.

Picolinamides were first introduced by Daugulis as a powerful directing group for site selective C–H metallation using palladium.⁵ Subsequently, a number of C–H bond functionalization reactions were developed by various research groups.⁶ In 2009, Liang *et al.* reported an *ortho*-C–H acetoxylation of benzyl amine derived picolinamides.⁷ A fused [5,5]-palladacycle was believed to be the key intermediate for the rate-limiting C–H



Scheme 1 Substrate design for benzylic acetoxylation using picolinamides as the bidenate directing group.

insertion step. Following a Pd(II)-Pd(IV)-Pd(II) oxidation-reductive elimination cycle, *o*-acetoxy benzyl amine derivatives were synthesized in high yields.⁸ Inspired by this result and related [5,5]-palladacycle reports,⁹ we decided to move the substrate arene one bond closer to the NH of the picolinamide, hoping that selective benzylic activation would occur in lieu of the *ortho*-aryl C–H functionalization (Scheme 1).

Results and discussion

The substrates were readily available following literature procedures from anilines and picolinic acid.¹⁰ Most commonly used transition-metals for C–H activation failed to yield any product, except palladium. We found that a combination of the substrate (0.1 mmol, 1 equiv.), 10% $Pd(OAc)_2$ and $PhI(OAc)_2$ (0.2 mmol, 2 equiv.) in DCE at 110 °C for 24 h produced the desired benzyl acetate in 40% yield. Encouraged by this result, we surveyed other reaction parameters (Table 1, for the comprehensive investigation of reaction parameters, see ESI†). The highest conversion was observed in toluene among

^aKey Laboratory of Chemical Genomics, School of Chemical Biology and Biotechnology, Peking University, Shenzhen Graduate School, Shenzhen, 518055, China. E-mail: huangyong@pkusz.edu.cn

^bDivision of Food-borne Diseases Surveillance, China National Center for Food Safety Risk Assessment, Building 2, Guangqu Road 37, Beijing, 100022, China

[†] Electronic supplementary information (ESI) available: Comprehensive reaction condition survey; kinetic experiments and images of ¹H and ¹³C NMR of all products. CCDC 969094. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c30b42196a



Entry	Cat.	Solvent	Additive	Conv. ^{b} (%)
1	$Fe(acac)_3$	DCE	_	N.R.
2	$Ni(acac)_2$	DCE	_	N.R.
3	Cp(Ph ₃ P) ₂ RuCl	DCE	_	N.R.
4	$[RhCp*Cl_2]_2$	DCE	_	N.R.
5	$Rh(OAc)_2$	DCE	_	N.R.
6	$Pd(OAc)_2$	DCE	_	40
7	$Pd(OAc)_2$	Toluene	_	50
8	$Pd(OAc)_2$	DMF	_	25
9	$Pd(OAc)_2$	PivOH	_	30
10	$Pd(OAc)_2$	Toluene/HOAc	_	50
11	$Pd(OAc)_2$	Toluene	Li_2CO_3	48
12	$Pd(OAc)_2$	Toluene	KF	29
13	$Pd(OAc)_2$	Toluene	KOH	N.R.
14	$Pd(OAc)_2$	Toluene	KHCO ₃	N.R.
15	$Pd(OAc)_2$	Toluene	Na_2CO_3	27
16	$Pd(OAc)_{2}$	Toluene	AgOAc	36
17	$Pd(OAc)_2$	Toluene	_	72^c

^{*a*} Reaction conditions: **1a** (22.6 mg, 0.1 mmol, 1 equiv.), $PhI(OAc)_2$ (64 mg, 0.2 mmol, 2 equiv.), additive (0.1 mmol, 1 equiv.) and catalyst (0.01 mmol, 0.1 equiv.) in a solvent (1 mL) under argon at 110 °C for 24 h. ^{*b*} The conversion was calculated by GC-MS using biphenyl as the internal standard. ^{*c*} Isolated yield after 48 h.

the solvents examined. Various bases were tested in an attempt to facilitate the chelation of the metal. No improvement was observed. The reaction was sensitive to the reaction temperature. Decreasing the temperature from 110 °C to 90 °C led to 20% conversion after 24 hours. Further increasing temperature resulted in substrate decomposition and attenuated yields. Fortunately, the active catalyst species was quite robust at 110 °C and prolonging the reaction time to 2 days afforded 72% isolated yield.

With the optimized conditions in hand, the substrate scope for benzylic oxidation was examined using various aniline derivatives (Table 2). This method was broadly applicable to a variety of aniline derived picolinamides. Aryl substituents of various electronic characteristics had little effect on both reaction rate and yield (entries 1–6, Table 2). When *N*-(*o*-tolyl)picolinamide was used, complete sp³ selectivity was observed and the 2-(picolinamido)benzyl acetate **2j** was isolated as the sole product. Multisubstituted aryl picolinamides were well tolerated, except for aniline derivatives having both *ortho*-positions substituted.

The standard reaction condition was challenged by using difficult substrates (secondary benzylic C–H bonds and aliphatic C–H bonds). The double benzylic substrate **10** was successfully acetoxylated in 69% yield (entry **1**, Table 3). The reaction of the *o*-ethyl aniline derived picolinamide **1p**, on the other hand, was very sluggish and the product was obtained in 45% yield. When the *N*-(2-*tert*-butylphenyl) picolinamide **1q** was used, the dihydroindole product was isolated as a result of C–N bond formation.¹¹ A similar cyclization was also observed

Table 2 Palladium-catalyzed acetoxylation of o-tolyl picolinamides^a

	<u>,</u>			
		Pd(OAc) ₂ . PhI(OAc) ₂ toluene, 110 °C, 48 hrs		
Entry	Substrate	Product		$\operatorname{Yield}^{b}(\%)$
1		Me NH OAC	2a	72
2		Br N N OAc	2b	69
3		F N OAC	2c	70
4			2d	82
5			2e	83
6			2f	84
7			2g	82
8			2h	60
9			2i	67
10			2j	85
11			2k	76
12			21	67
13			2m	70
14			2n	70

^{*a*} Reaction conditions: picolinamide 1 (0.5 mmol, 1.0 equiv.), PhI(OAc)₂, (322 mg, 1.0 mmol, 2 equiv.) and Pd(OAc)₂ (11.4 mg, 0.1 mmol, 0.1 equiv.) in toluene (5 mL) under argon at 110 °C for 48 hours. ^{*b*} Isolated yield.

 Table 3
 Reactions of other substrates^a



 a 0.5 mmol scale. b Isolated yield. c Another portion of PhI(OAc)_2 (64 mg, 0.2 mmol, 2 equiv.) was added after 24 h.

for isobutyl picolinamide **1s**. Successful aliphatic sp³ acetoxylation was obtained for *N*-(2-methylcyclohexyl) picolinamide **1r** (62% yield, entry 4, Table 3). Rotational restriction of the substrate forces the methyl group and the directing group in close proximity so that the C-H activation occurs more readily. Interestingly, both the *trans*- and *cis*-isomer of **1s** reacted at similar rates. When a mixture of *trans*- and *cis*-isomers was used, the ratio of *trans*- and *cis*-products was very close to that of the starting material, indicating similar reactivity for both isomers.

The kinetics of the acetoxylation reaction was measured. Interestingly, this reaction required an initial aging period, possibly due to the trace amount of oxygen in the system. When carried out in a glovebox, the acetoxylation for **1a** reached 50% conversion in 4 hours, whereas the same experiment using the traditional degas/refill technique required 12 hours to reach comparable conversion. The reaction is first order to the concentration of the substrate and an initial rate of 9×10^{-4} M min⁻¹ was determined by GC. The C-H bond cleavage was evidently the rate-limiting step, supported by a large isotope effect ($k_{\rm H}/k_{\rm D} = 4.5$, Scheme 2). The benzylic C-H insertion was irreversible as the deuterated substrate had no isotope scrambling after the reaction.



Scheme 2 Kinetics and isotope effects.





2j k₁ = 0.0009 M/mir

Substrates bearing additional methyl groups exhibited some degree of rate discrepancy, depending on the substitution pattern. The initial rates of those substrates were determined individually and results are summarized in Scheme 3. When a methyl group was introduced next to the reacting methyl, the initial rate of the reaction increased to $k_2 = 0.0012$ M min⁻¹; when the methyl group was moved to the 4- and 5-position, the reaction rates decreased to 0.0006 M min⁻¹. A 6-methyl group resulted in complete reaction inhibition. In order to better understand the substitution effect, substrate **1j** was heated with Pd(OAc)₂ (1:1) in toluene at 110 °C. A large amount of yellow solid formed after 5 min. The structure of this solid was determined as a dimeric palladium amide by X-ray. The attempt to intercept the benzyl palladium intermediate was unsuccessful.

We speculated that substitution at 5- and 6-positions would restrict free rotation of the Aryl–N bond so that effective palladium insertion would be more difficult compared to the nonsubstituted substrate. In contrast, steric repulsion from the 3-methyl substrate forces the reacting 2-methyl group closer to the palladium, facilitating the C–H metallation step. It remains elusive why the dismal 4-methyl substituent also showed diminished reactivity. One explanation could be slow dissociation of the dimer complex. Detailed mechanistic and theoretical investigations are currently underway.

The acetoxylated products could be readily hydrolyzed under basic conditions to generate the 2-amino benzyl alcohols which were transformed to several heterocycles of medicinal chemistry interest (Scheme 4). Condensation of **3a** with acetophenone in the presence of *t*-BuOK resulted in the corresponding quinoline in 75% yield.¹² Acid promoted cycloaddition with 3-methyl indole rendered 5,6-fused indoline aminals, which are widely found in the *Communesin* family natural products.¹³ Reductive amination using *o*-nitrobenz-aldehyde, followed by base mediated cyclization afforded the 5*H*-benzo[4,5][1,3]oxazino[3,2-*b*]indazole scaffold.¹⁴

Conclusions

In summary, we developed a general protocol for Pd catalyzed acetoxylation of benzylic C-H bonds by employing a bidenate



Scheme 4 Synthesis of various heterocycles using the 2-amino benzyl acetate product.

picolinamide as the directing group. This transformation has broad functional group tolerance and interesting mechanistic aspects. The benzyl acetate products demonstrated far-reaching utilization for heterocycle synthesis.

Experimental

General methods

All reactions were carried out under an argon atmosphere with dry solvents under anhydrous conditions. All other reagents were purchased and used without further purification unless specified otherwise. Toluene was distilled from CaH₂ prior to use. Solvents for chromatography were technical grade and distilled prior to use. Flash chromatography was performed using 200-300 mesh silica gel with the indicated solvent system according to standard techniques. Analytical thin-layer chromatography (TLC) was performed using Huanghai silica gel plates with HSGF 254. Qingdao Haiyang Chemical HG/T2354-92 silica gel was used for silica gel flash chromatography. Visualization of the developed chromatogram was performed by UV absorbance (254 nm) or appropriate stains. ¹H NMR and ¹³C NMR data were recorded on Bruker 400 MHz nuclear resonance spectrometers unless otherwise specified, respectively. Chemical shifts (δ) in ppm are reported as quoted relative to the residual signals of chloroform (¹H 7.26 ppm or ¹³C 77.16 ppm). Multiplicities are described as: s (singlet), bs (broad singlet), d (doublet), t (triplet), q (quartet), m (multiplet); and coupling constants (J) are reported in hertz (Hz). ¹³C NMR spectra were recorded with total proton decoupling. HRMS (ESI) analysis was performed by The Analytical Instrumentation Center at Peking University, Shenzhen Graduate School and (HRMS) data were reported with ion mass/charge (m/z) ratios as values in atomic mass units.

General procedure for palladium catalysed acetoxylation of benzylic C–H bonds

The picolinamide 1 (0.5 mmol, 1.0 equiv.), $PhI(OAc)_2$, (322 mg, 1.0 mmol, 2 equiv.) and $Pd(OAc)_2$ (11.4 mg, 0.1 mmol,

0.1 equiv.) were placed in a Schlenk tube and capped with a rubber septum. The reaction vessel was degassed and back-filled with argon three times. Toluene (5 mL) was added *via* a syringe. The reaction mixture was stirred at 110 °C for 48 hours, cooled to room temperature and concentrated in vacuum. The residue was purified by silica gel column flash chromatography (eluent: hexane–EtOAc) to give compound **2**.

4-Methyl-2-(picolinamido)benzyl acetate (2a). 102 mg, 72%; ¹H NMR (300 MHz, CDCl₃) δ 10.58 (s, 1H), 8.67–8.56 (m, 1H), 8.31 (d, *J* = 7.8 Hz, 1H), 8.15 (s, 1H), 7.93 (m, 1H), 7.50 (m, 1H), 7.26 (d, *J* = 6.7 Hz, 1H), 6.99 (d, *J* = 7.7 Hz, 1H), 5.17 (s, 2H), 2.41 (s, 3H), 2.20 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 170.90, 162.33, 149.99, 148.12, 140.03, 137.68, 136.70, 130.32, 126.52, 125.42, 123.07, 123.01, 122.53, 64.42, 21.54, 20.95; HRMS (ESI-TOF) calcd for C₁₆H₁₆N₂NaO₃ ([M + Na⁺]) = 307.1059, found: 307.1053.

4-Bromo-2-(picolinamido)benzyl acetate (2b). 120 mg, 69%; ¹H NMR (500 MHz, CDCl₃) δ 10.64 (s, 1H), 8.62 (d, *J* = 4.4 Hz, 1H), 8.59 (s, 1H), 8.30 (d, *J* = 7.8 Hz, 1H), 7.94 (t, *J* = 7.6 Hz, 1H), 7.59–7.47 (m, 1H), 7.26 (m, 2H), 5.16 (s, 2H), 2.20 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 170.51, 162.31, 149.65, 148.13, 138.10, 137.73, 131.46, 127.47, 126.70, 125.13, 124.59, 123.48, 122.63, 63.79, 20.74; HRMS (ESI-TOF) calcd for C₁₅H₁₃BrN₂NaO₃ ([M + Na⁺]) = 371.0007, found: 371.0001.

4-Fluoro-2-(picolinamido)benzyl acetate (2c). 101 mg, 70%; ¹H NMR (400 MHz, CDCl₃) δ 10.72 (s, 1H), 8.61 (d, *J* = 4.1 Hz, 1H), 8.30 (d, *J* = 7.6 Hz, 1H), 8.22 (d, *J* = 10.9 Hz, 1H), 7.93 (t, *J* = 7.6 Hz, 1H), 7.55–7.45 (m, 1H), 7.36–7.29 (m, 1H), 6.84 (t, *J* = 8.0 Hz, 1H), 5.18 (s, 2H), 2.20 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 170.75, 164.52, 162.21, 149.59, 148.17, 138.56, 137.79, 131.70, 126.78, 122.63, 121.03, 111.02, 109.34, 63.92, 20.87; HRMS (ESI-TOF) calcd for $C_{15}H_{13}FN_2NaO_3$ ([M + Na⁺]) = 311.0808, found: 311.0801.

(3-(Picolinamido)-[1,1'-biphenyl]-4-yl)methyl acetate (2d). 142 mg, 82%; ¹H NMR (400 MHz, CDCl₃) δ 10.69 (s, 1H), 8.63 (d, *J* = 1.5 Hz, 2H), 8.33 (d, *J* = 7.7 Hz, 1H), 7.93 (td, *J* = 7.7, 1.4 Hz, 1H), 7.68 (d, *J* = 7.3 Hz, 2H), 7.50–7.35 (m, 6H), 5.26 (s, 2H), 2.23 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 170.87, 162.48, 149.93, 148.17, 142.82, 140.31, 137.76, 137.27, 130.80, 128.79, 127.70, 127.31, 126.63, 124.77, 123.23, 122.57, 121.19, 64.32, 20.95; HRMS (ESI-TOF) calcd for C₂₁H₁₈N₂NaO₃ ([M + Na⁺]) = 369.1215, found: 369.1212.

Methyl 3-(acetoxymethyl)-4-(picolinamido)benzoate (2e). 136 mg, 83%; ¹H NMR (400 MHz, CDCl₃) δ 10.63 (s, 1H), 8.92 (s, 1H), 8.63 (d, J = 4.6 Hz, 1H), 8.33 (d, J = 7.8 Hz, 1H), 7.98–7.90 (m, 1H), 7.89–7.84 (m, 1H), 7.52 (dd, J = 6.9, 5.0 Hz, 1H), 7.46 (d, J = 7.9 Hz, 1H), 5.24 (s, 2H), 3.94 (s, 3H), 2.22 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 170.54, 166.44, 162.45, 149.64, 148.15, 137.74, 136.82, 131.50, 130.75, 130.08, 126.70, 125.84, 123.58, 122.64, 63.90, 52.24, 20.78; HRMS (ESI-TOF) calcd for C₁₇H₁₆N₂NaO₅ ([M + Na⁺]) = 351.0957, found: 351.0961.

5-Methoxy-2-(picolinamido)benzyl acetate (2f). 126 mg, 84%; ¹H NMR (300 MHz, CDCl₃) δ 10.40 (s, 1H), 8.62 (d, J = 4.4 Hz, 1H), 8.31 (d, J = 7.8 Hz, 1H), 8.07 (d, J = 8.7 Hz, 1H), 7.92 (t, J = 7.2 Hz, 1H), 7.50 (dd, J = 6.8, 5.2 Hz, 1H), 6.97 (dd,

$$\begin{split} J &= 12.1, \ 3.2 \ \text{Hz}, \ 2\text{H}), \ 5.16 \ (\text{s}, \ 2\text{H}), \ 3.84 \ (\text{s}, \ 3\text{H}), \ 2.21 \ (\text{s}, \ 3\text{H}); \ ^{13}\text{C} \\ \text{NMR} \ (75 \ \text{MHz}, \ \text{CDCl}_3) \ \delta \ 170.87, \ 162.45, \ 156.68, \ 149.96, \ 148.13, \\ 137.64, \ 129.52, \ 128.36, \ 126.45, \ 124.73, \ 122.50, \ 115.73, \ 114.40, \\ 64.29, \ 55.56, \ 20.91; \ \text{HRMS} \ (\text{ESI-TOF}) \ \text{calcd} \ \text{for} \ \ C_{16}\text{H}_{16}\text{N}_2\text{NaO}_4 \ ([\text{M} + \text{Na}^+]) = 323.1008, \ \text{found:} \ 323.1013. \end{split}$$

5-Chloro-2-(picolinamido)benzyl acetate (2g). 125 mg, 82%; ¹H NMR (400 MHz, CDCl₃) δ 10.58 (s, 1H), 8.61 (d, J = 4.4 Hz, 1H), 8.27 (dd, J = 12.5, 8.2 Hz, 2H), 7.92 (td, J = 7.7, 1.5 Hz, 1H), 7.54–7.44 (m, 1H), 7.42–7.33 (m, 2H), 5.16 (s, 2H), 2.20 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 170.65, 162.41, 149.63, 148.17, 137.76, 135.33, 130.04, 129.63, 129.59, 127.72, 126.72, 123.78, 122.62, 63.66, 20.83; HRMS (ESI-TOF) calcd for C₁₅H₁₃ClN₂NaO₃ ([M + Na⁺]) = 327.0512, found: 327.0509.

2-Fluoro-6-(picolinamido)benzyl acetate (2h). 60 mg, 60%; ¹H NMR (400 MHz, CDCl₃) δ 10.81 (s, 1H), 8.63 (d, *J* = 4.3 Hz, 1H), 8.30 (d, *J* = 7.8 Hz, 1H), 8.12 (d, *J* = 8.3 Hz, 1H), 7.92 (t, *J* = 7.6 Hz, 1H), 7.54–7.44 (m, 1H), 7.40 (dd, *J* = 15.0, 7.8 Hz, 1H), 6.92 (t, *J* = 8.8 Hz, 1H), 5.29 (s, 2H), 2.20 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 171.08, 162.63, 160.10, 149.76, 148.23, 138.59, 137.70, 130.66, 126.69, 122.66, 118.28, 113.98, 111.43, 56.72, 20.80; HRMS (ESI-TOF) calcd for C₁₅H₁₃FN₂NaO₃ ([M + Na⁺]) = 311.0808, found: 311.0810.

2-Chloro-6-(picolinamido)benzyl acetate (2i). 102 mg, 67%; ¹H NMR (400 MHz, CDCl₃) δ 10.87 (s, 1H), 8.65 (s, 1H), 8.31 (d, *J* = 7.1 Hz, 1H), 8.18 (d, *J* = 7.9 Hz, 1H), 7.93 (s, 1H), 7.52 (s, 1H), 7.36 (d, *J* = 7.9 Hz, 1H), 7.26 (d, *J* = 7.6 Hz, 1H), 5.40 (s, 2H), 2.22 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 171.17, 162.69, 149.75, 148.26, 138.74, 137.70, 135.46, 130.35, 126.70, 125.91, 124.36, 122.69, 121.78, 60.70, 20.81; HRMS (ESI-TOF) calcd for C₁₅H₁₃ClN₂NaO₃ ([M + Na⁺]) = 327.0512, found: 327.0518.

2-(Picolinamido)benzyl acetate (2j). 115 mg, 85%; ¹H NMR (500 MHz, CDCl₃) δ 10.62 (s, 1H), 8.64 (d, *J* = 4.1 Hz, 1H), 8.33 (d, *J* = 7.9 Hz, 2H), 7.94 (m, 1H), 7.51 (m, 1H), 7.46 (m, 1H), 7.40 (d, *J* = 6.9 Hz, 1H), 7.20 (t, *J* = 7.5 Hz, 1H), 5.23 (s, 2H), 2.23 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 170.66, 162.34, 150.08, 148.09, 137.62, 136.91, 130.28, 129.74, 126.46, 126.02, 124.62, 122.55(2C), 64.49, 20.82; HRMS (ESI-TOF) calcd for C₁₅H₁₄N₂NaO₃ ([M + Na⁺]) = 293.0902, found: 293.0910.

5-Bromo-4-fluoro-2-(picolinamido)benzyl acetate (2k). 140 mg, 76%; ¹H NMR (500 MHz, CDCl₃) δ 10.71 (s, 1H), 8.62 (d, *J* = 3.8 Hz, 1H), 8.34 (d, *J* = 10.7, 1H), 8.30 (d, *J* = 7.6 Hz, 1H), 7.94 (t, *J* = 7.4 Hz, 1H), 7.53 (m, 2H), 5.15 (s, 2H), 2.20 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 170.60, 162.36, 160.63, 158.17, 149.35, 148.20, 137.86, 137.67, 134.61, 126.92, 122.70, 110.23, 103.19, 63.11, 20.82; HRMS (ESI-TOF) calcd for $C_{15}H_{12}BrFN_2NaO_3$ ([M + Na⁺]) = 388.9913, found: 388.9920.

4-Bromo-5-chloro-2-(picolinamido)benzyl acetate (2l). 129 mg, 67%; ¹H NMR (400 MHz, CDCl₃) δ 10.66 (s, 1H), 8.63 (d, *J* = 4.4 Hz, 1H), 8.59 (s, 1H), 8.30 (d, *J* = 7.7 Hz, 1H), 7.95 (m, 1H), 7.62 (s, 1H), 7.54 (m, 1H), 5.16 (s, 2H), 2.22 (s, 3H);¹³C NMR (100 MHz, CDCl₃) δ 170.54, 162.34, 149.32, 148.21, 137.85, 136.87, 135.54, 134.68, 126.91, 125.72, 123.55, 122.68, 116.94, 63.02, 20.80; HRMS (ESI-TOF) calcd for C₁₅H₁₂BrClN₂NaO₃ ([M + Na⁺]) = 404.9618, found: 404.9623.

2-Methyl-6-(picolinamido)benzyl acetate (2m). 100 mg, 70%; ¹H NMR (500 MHz, $CDCl_3$) δ 10.72 (s, 1H), 8.65 (d,

J = 4.6 Hz, 1H), 8.31 (d, *J* = 7.8 Hz, 1H), 8.00 (d, *J* = 8.1 Hz, 1H), 7.92 (td, *J* = 7.7, 1.6 Hz, 1H), 7.50–7.48 (m, 1H), 7.33 (t, *J* = 7.9 Hz, 1H), 7.06 (d, *J* = 7.6 Hz, 1H), 5.27 (s, 2H), 2.47 (s, 3H), 2.17 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 171.31, 162.76, 150.12, 148.25, 138.50, 137.58, 137.18, 129.34, 127.18, 126.46, 125.33, 122.59, 121.47, 60.48, 20.88, 19.74; HRMS (ESI-TOF) calcd for $C_{16}H_{16}N_2NaO_3$ ([M + Na⁺]) = 307.1059, found: 307.1065.

5-Methyl-2-(picolinamido)benzyl acetate (2n). 100 mg, 70%; ¹H NMR (500 MHz, CDCl₃) δ 10.50 (s, 1H), 8.61 (d, *J* = 4.3 Hz, 1H), 8.31 (d, *J* = 7.8 Hz, 1H), 8.14 (d, *J* = 8.2 Hz, 1H), 7.91 (td, *J* = 7.7, 1.5 Hz, 1H), 7.49 (dd, *J* = 6.7, 4.9 Hz, 1H), 7.26–7.22 (m, 1H), 7.18 (s, 1H), 5.17 (s, 2H), 2.36 (s, 3H), 2.20 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 170.81, 162.32, 150.09, 148.10, 137.62, 134.46, 134.23, 130.89, 130.29, 126.43, 126.06, 122.71, 122.52, 64.53, 20.90, 20.84; HRMS (ESI-TOF) calcd for $C_{16}H_{16}N_2NaO_3$ ([M + Na⁺]) = 307.1059, found: 307.1065.

Phenyl(2-(picolinamido)phenyl)methyl acetate (20). 120 mg, 69%; ¹H NMR (400 MHz, CDCl₃) δ 10.59 (s, 1H), 8.61–8.60 (m, 1H), 8.28 (dd, J = 13.2, 8.0 Hz, 2H), 7.87 (td, J = 7.7, 1.7 Hz, 1H), 7.50–7.43 (m, 1H), 7.43–7.35 (m, 4H), 7.33–7.23 (m, 3H), 7.23–7.15 (m, 1H), 7.08 (s, 1H), 2.26 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 169.97, 162.35, 149.90, 147.96, 138.44, 137.58, 135.71, 130.40, 129.21, 128.94, 128.47, 128.04, 126.87, 126.46, 124.85, 123.38, 122.48, 74.93, 21.19; HRMS (ESI-TOF) calcd for C₂₁H₁₈N₂NaO₃ ([M + Na⁺]) = 369.1215, found: 369.1220.

1-(2-(Picolinamido)phenyl)ethyl acetate (2p). 64 mg, 45%; ¹H NMR (400 MHz, CDCl₃) δ 10.86 (s, 1H), 8.65 (d, *J* = 4.1 Hz, 1H), 8.32 (d, *J* = 7.8 Hz, 1H), 8.24 (d, *J* = 7.9 Hz, 1H), 7.92 (td, *J* = 7.7, 1.7 Hz, 1H), 7.49 (m, 1H), 7.39 (dd, *J* = 12.1, 4.5 Hz, 2H), 7.24–7.12 (m, 1H), 6.03 (q, *J* = 6.7 Hz, 1H), 2.17 (s, 3H), 1.62 (d, *J* = 6.7 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 170.42, 162.57, 150.17, 148.21, 137.61, 135.41, 131.54, 128.97, 127.52, 126.44, 125.02, 123.51, 122.59, 70.97, 21.25, 20.50; HRMS (ESI-TOF) calcd for C₁₆H₁₆N₂NaO₃ ([M + Na⁺]) = 307.1059, found: 307.1065.

(3,3-Dimethylindolin-1-yl)(pyridin-2-yl)methanone (2q). 67 mg, 53%; ¹H NMR (300 MHz, CDCl₃) δ 8.64 (d, *J* = 4.4 Hz, 1H), 8.29 (d, *J* = 8.0 Hz, 1H), 7.87 (m, 2H), 7.53–7.33 (m, 1H), 7.33–7.23 (m, 1H), 7.22–7.06 (m, 2H), 4.09 (s, 2H), 1.33 (s, 6H); ¹³C NMR (75 MHz, CDCl₃) δ 166.08, 154.57, 148.15, 142.05, 141.54, 137.21, 127.71, 125.17, 124.80, 124.42, 121.99, 118.04, 65.15, 40.73, 30.42, 28.30; HRMS (ESI-TOF) calcd for C₁₆H₁₆N₂NaO ([M + Na⁺]) = 275.1160, found: 275.1165.

(2-(Picolinamido)cyclohexyl)methyl acetate (2r). 86 mg, 62%; ¹H NMR (500 MHz, CDCl₃) δ 8.60–8.49 (m, 1H), 8.19 (d, J = 7.8 Hz, 1H), 8.01 (d, J = 8.6 Hz, 1H), 7.85 (td, J = 7.7, 1.7 Hz, 1H), 7.42 (m, 1H), 4.11 (m, 1H), 4.00 (dd, J = 11.2, 6.2 Hz, 1H), 3.90 (m, 1H), 2.17–2.06 (m, 1H), 1.98 (s, 3H), 1.95–1.85 (m, 1H), 1.77 (m, 3H), 1.41 (m, 1H), 1.35–1.24 (m, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 171.18, 163.64, 149.86, 147.93, 137.40, 126.14, 122.34, 66.89, 50.21, 42.54, 33.44, 29.00, 25.15, 25.09, 20.89; HRMS (ESI-TOF) calcd for C₁₅H₂₀N₂NaO₃ ([M + Na⁺]) = 299.1372, found: 299.1380.

(3-Methylazetidin-1-yl)(pyridin-2-yl)methanone (2s). 70 mg, 80%; ¹H NMR (500 MHz, CDCl₃) δ 8.56 (d, *J* = 4.2 Hz, 1H), 8.08

Organic & Biomolecular Chemistry

(d, J = 7.8 Hz, 1H), 7.78 (dd, J = 10.9, 4.5 Hz, 1H), 7.34 (m, 1H), 4.79 (t, J = 9.2 Hz, 1H), 4.34 (t, J = 9.3 Hz, 1H), 4.25 (dd, J = 10.2, 5.6 Hz, 1H), 3.79 (dd, J = 10.2, 5.5 Hz, 1H), 2.77 (m, 1H), 1.27 (t, J = 10.6 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 165.34, 152.13, 148.03, 136.75, 125.16, 123.75, 61.65, 55.71, 24.89, 19.67; HRMS (ESI-TOF) calcd for C₁₀H₁₂N₂NaO ([M + Na⁺]) = 199.0847, found: 199.0853.

Product derivatization

(2-Amino-4-methylphenyl)methanol (3a). Compound 2a (570 mg, 2.0 mmol, 1 equiv.) and NaOH (320 mg, 8.0 mmol, 4 equiv.) were heated in ethanol (10 mL) for 8 hours at 70 °C. EtOH was removed under vacuum. The residue was dissolved in EtOAc, neutralized with sat. NH_4Cl , washed with water and extracted with EtOAc 3 times. The combined organic layer was washed with brine, dried over anhydrous Na_2SO_4 , filtered and concentrated under vacuum to give compound 3a as a yellow solid (260 mg 95%) and used directly in the next step without purification.

(5aR*,10bS*)-6,10b-Dimethyl-5a,6,10b,11-tetrahydro-5H-indolo-[2,3-b]quinolone (4a). Compound 3a (27.4 mg, 0.2 mmol, 1 equiv.) and 3-methyl indole (58.08 mg, 0.4 mmol, 2 equiv.) were dissolved in DCE (1 mL), and TFA (6.8 mg, 0.06 mmol, 0.3 equiv.) was added. The reaction was stirred at 50 °C for 3 hours, cooled to room temperature, and washed with sat. aqueous NaHCO3 solution. The aqueous layer was extracted with DCM three times. The combined organic layer was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel column flash chromatography (EtOAc-hexane = 1:20) to give compound 4a (40 mg, 80%) as a white solid. ¹H NMR $(500 \text{ MHz}, \text{CDCl}_3) \delta$ 7.14 (dd, J = 13.8, 7.1 Hz, 2H), 6.89 (d, J = 13.8, 7.1 Hz, 2H)7.4 Hz, 1H), 6.79 (t, J = 7.4 Hz, 1H), 6.53 (t, J = 8.3 Hz, 2H), 6.48 (s, 1H), 4.60 (s, 1H), 4.13 (d, J = 14.2 Hz, 1H), 2.78 (s, 3H), 2.76 (s, 1H) 2.48 (d, J = 15.1 Hz, 1H), 2.28 (s, 3H), 1.24 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 149.19, 140.86, 137.21, 136.67, 128.95, 127.71, 121.31, 118.77, 118.57, 114.07, 107.95, 83.78, 38.95, 37.13, 32.13, 30.95, 21.39, 21.28; HRMS (ESI-TOF) calcd for $C_{18}H_{20}N_2Na$ ([M + Na⁺]) = 287.1524, found: 287.1534.

3-(4-Bromophenyl)-7-methylquinoline (5a). To a solution of compound 3a (27 mg, 0.2 mmol, 1 equiv.) in 1,4-dioxane (1 mL) were added 4-bromo benzophenone (40 mg, 0.2 mmol, 1 equiv.) and tBuOK (22 mg, 0.2 mmol, 1 equiv.) under argon. The resulting solution was heated at 90 °C for 30 minutes. The reaction mixture was poured into sat. aqueous solution of NH₄Cl (10 mL) and extracted with EtOAc three times. The combined organic layer was back extracted using dilute HCl (2 M, 3×10 mL). The combined aqueous phase was treated with NaOH solution until pH = 13, and extracted with EtOAc 3 times. The combined organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated to give compound 5a (45 mg, 75%). ¹H NMR (500 MHz, CDCl₃) δ 8.20 (d, J = 8.6 Hz, 1H), 8.07 (d, J = 8.6 Hz, 2H), 7.97 (s, 1H), 7.80 (d, J = 8.5 Hz, 1H), 7.75 (d, J = 8.3 Hz, 1H), 7.67 (d, J = 8.6 Hz, 2H), 7.43-7.36 (m, 1H), 2.61 (s, 3H); ¹³C NMR (125 MHz, CDCl₃)

 δ 156.00, 148.51, 140.15, 138.69, 136.60, 131.91, 129.06, 128.79, 128.72, 127.10, 125.34, 123.78, 117.68, 21.85; HRMS (ESI-TOF) calcd for $C_{16}H_{12}BrNNa~([M~+~Na^+])$ = 320.0051, found: 320.0060.

2-Methyl-5H-benzo[4,5][1,3]oxazino[3,2-b]indazole (6a). 2-Nitrobenzaldehyde (50 mg, 0.33 mmol, 1 equiv.) and compound 3a (44 mg, 0.36 mmol, 1.1 equiv.) were dissolved in methanol (1.6 mL). The resulting solution was stirred at room temperature for 5 minutes before HOAc (1.6 mmol, 4.8 equiv.) was added. The mixture was stirred under argon for 3 hours. Then NaCH₃CN (1.32 mmol, 4 equiv.) was added. The reaction was stirred for 3 hours. The solvent was removed under vacuum. The residue was dissolved in iPrOH (3.5 mL). KOH (10% w/w) was added and the basic solution was stirred for 3 hours. The reaction was concentrated and the residue was dissolved in EtOAc and washed with water. The aqueous phase was extracted with EtOAc three times. The combined organic layer was washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel flash column chromatography (EtOAc-hexane = 1:10) to give compound 6a (55 mg, 70%). ¹H NMR (500 MHz, MeOD) δ 7.72 (s, 1H), 7.54 (d, J = 8.5 Hz, 1H), 7.46 (d, J = 8.9 Hz, 1H), 7.29 (dd, J = 13.2, 7.6 Hz, 2H), 7.20 (d, J = 7.6 Hz, 1H), 7.00–6.89 (m, 1H), 5.50 (s, 2H), 2.46 (s, 3H); ¹³C NMR (75 MHz, MeOD) δ 148.87, 140.07, 132.77, 129.43, 128.50, 127.61, 124.90, 120.16, 118.97, 118.88, 115.93, 115.46, 106.42, 68.17, 20.08; HRMS (ESI-TOF) calcd for $C_{15}H_{13}N_2O([M + H^+]) = 237.1028$, found: 237.1030.

Acknowledgements

This work was financially supported by grants of the National Basic Research Program of China (2010CB833201), National Natural Science Foundation of China (21372013), the Shenzhen Peacock Program (KQTD201103) and Shenzhen innovation funds (GJHZ20120614144733420). Y. H. thanks the MOE for the Program for New Century Excellent Talents in University. The Shenzhen municipal development and reform commission is thanked for a public service platform program.

Notes and references

 For recent reviews on C-H activation, see: (a) C. Wang and Y. Huang, Synlett, 2013, 145; (b) H. Ohno, Asian J. Org. Chem., 2013, 2, 18; (c) S. I. Kozhushkov, H. K. Potukuchi and L. Ackermann, Catal. Sci. Technol., 2013, 3, 562; (d) S. I. Kozhushkov and L. Ackermann, Chem. Sci., 2013, 4, 886; (e) M. Zhang, A.-Q. Zhang and Y. Peng, J. Organomet. Chem., 2013, 723, 224; (f) N. Kuhl, M. N. Hopkinson, J. Wencel-Delord and F. Glorius, Angew. Chem., Int. Ed., 2012, 51, 10236; (g) C. Zhu, R. Wang and J. R. Falck, Asian Chem. J., 2012, 7, 1502; (h) D. Y.-K. Chen and S. W. Youn, Eur. J. Chem., 2012, 18, 9452; (i) Y. Deng, A. K. Å. Persson and J.-E. Bäckvall, *Chem.-Eur. J.*, 2012, **18**, 11498; (*j*) G. Song, F. Wang and X. Li, *Chem. Soc. Rev.*, 2012, **41**, 3651; (*k*) B.-J. Li and Z.-J. Shi, *Chem. Soc. Rev.*, 2012, **41**, 5588; (*l*) L. Ackermann, *Chem. Rev.*, 2011, **111**, 1315.

- 2 For recent reviews on sp³ C-H activation: (a) O. Baudoin, *Chem. Soc. Rev.*, 2011, 40, 4902; (b) T. Newhouse and P. S. Baran, *Angew. Chem., Int. Ed.*, 2011, 50, 3362.
- 3 For recent examples on sp^3 C–H oxygenation reactions, see: (a) M. A. Bigi, S. A. Reed and M. C. White, J. Am. Chem. Soc., 2012, 134, 9721; (b) S.-Y. Zhang, G. He, Y. Zhao, K. Wright, W. A. Nack and G. Chen, J. Am. Chem. Soc., 2012, 134, 7313; (c) Y.-F. Wang, H. Chen, X. Zhu and S. Chiba, J. Am. Chem. Soc., 2012, 134, 11980; (d) Z. Ren, F. Mo and G. Dong, J. Am. Chem. Soc., 2012, 134, 16991; (e) E. M. Simmons and J. F. Hartwig, Nature, 2012, 483, 70; (f) R. K. Rit, M. R. Yadav and A. K. Sahoo, Org. Lett., 2012, 14, 3724; (g) K. J. Stowers, A. Kubota and M. S. Sanford, Chem. Sci., 2012, 3, 3192; (h) G. He and G. Chen, Angew. Chem., Int. Ed., 2011, 50, 5192; (i) P. Novák, A. Correa, J. Gallardo-Donaire and R. Martin, Angew. Chem., Int. Ed., 2011, 50, 12236; (j) X.-F. Hou, Y.-N. Wang and I. Göttker-Schnetmann, Organometallics, 2011, 30, 6053; (k) A. Kubota and M. S. Sanford, Synthesis, 2011, 2579; (l) H. Jiang, H. Chen, A. Wang and X. Liu, Chem. Commun., 2010, 46, 7259; (m) D.-H. Wang, X.-S. Hao, D.-F. Wu and J.-Q. Yu, Org. Lett., 2006, 8, 3387; (n) B. V. S. Reddy, L. R. Reddy and E. J. Corev, Org. Lett., 2006, 8, 3391; (o) L. V. Desai, K. L. Hull and M. S. Sanford, J. Am. Chem. Soc., 2004, 126, 9542.
- 4 During the preparation of this manuscript, a related acetoxylation reaction of benzylic C–H bond was published, see: L. Ju, J. Yao, Z. Wu, Z. Liu and Y. Zhang, *J. Org. Chem.*, 2013, **78**, 10821.

- 5 (a) D. Shabashow and O. Daugulis, Org. Lett., 2005, 7, 3657;
 (b) V. G. Zaitsev, D. Shabashov and O. Daugulis, J. Am. Chem. Soc., 2005, 127, 13154.
- 6 For a recent review on picolinamide type bidentate directing groups for C-H activation, see: (a) G. Rouquet and N. Chatani, Angew. Chem., Int. Ed., 2013, 52, 11726. For selected recent examples using picolinamides as the directing group, see: (b) W. A. Nack, G. He, S.-Y. Zhang, C. Lu and G. Chen, Org. Lett., 2013, 15, 3440; (c) R. Pearson, S. Zhang, G. He, N. Edwards and G. Chen, J. Org. Chem., 2013, 9, 891; (d) S. Zhang, G. He, W. A. Nack, Y. Zhao, Q. Li and G. Chen, J. Am. Chem. Soc., 2013, 135, 2124; (e) L. Huang, Q. Li, C. Wang and C. Qi, J. Org. Chem., 2013, 78, 3030; (f) Y. Zhao, G. He, W. A. Nack and G. Chen, Org. Lett., 2012, 14, 2948; (g) G. He, C. Lu, Y. Zhao, W. A. Nack and G. Chen, Org. Lett., 2012, 14, 2944.
- 7 F.-R. Gou, X.-C. Wang, P.-F. Huo, H.-P. Bi, Z.-H. Guan and Y.-M. Liang, *Org. Lett.*, 2009, **11**, 5726.
- 8 L. Guo, Y. Xu, X. Wang, W. Liu and D. Lu, *Organometallics*, 2013, **32**, 3780.
- 9 L. D. Tran and O. Daugulis, Angew. Chem., Int. Ed., 2012, 51, 5188.
- 10 Y. Xie, Y. Yang, L. Huang, X. Zhang and Y. Zhang, *Org. Lett.*, 2012, 14, 1238–1241.
- 11 G. He, Y. Zhao, S. Zhang, C. Lu and G. Chen, *J. Am. Chem. Soc.*, 2012, **134**, 3.
- 12 R. Martínez, D. J. Ramón and M. Yus, *J. Org. Chem.*, 2008, 73, 9778.
- 13 F. J. Robertson, B. D. Kenimer and J. Wu, *Tetrahedron*, 2011, 67, 4327.
- 14 B. Avila, D. M. Solano, M. J. Haddadin and M. J. Kurth, *Org. Lett.*, 2011, 13, 1060.